Abstract:
BACKGROUND:Adherence to disease-modifying therapies (DMTs) is essential for the reduction of multiple sclerosis (MS) progression and relapse. However, only limited data currently exist on the impact of treatment adherence on MS-related clinical and economic outcomes in the real world setting. OBJECTIVE:To assess the impact of treatment adherence on MS-related hospitalizations (inpatient [INP]), ER visits, MS relapses, and medical costs. DESIGN/METHODS:Patients with ≥ 1 ICD-9-CM code for MS who received ≥ 1 DMT between July 1, 2004 and June 30, 2008 were identified using the administrative claims database. The first DMT received during the study period was defined as the index treatment and ≥ 6-month preindex and ≥ 12-month postindex continuous health-plan enrollment were required for inclusion. Adherence was assessed using the medication possession ratio (MPR); patients with MPR ≥ 80% were regarded as adherent. Multivariate analyses were used to evaluate the impact of adherence on MS-related outcomes after controlling for baseline demographic and clinical characteristics. RESULTS:In this cohort (n=2446), 59.6% of the patients were adherent to their DMT. Compared with the nonadherent group, adherent patients were significantly less likely to have MS-related INP (odds ratio [OR]: 0.63, 95% confidence interval [CI], 0.47-0.83) and MS relapses (OR: 0.71, 95% CI, 0.59-0.85). No significant difference was found in ER risk between adherent and nonadherent groups (8.4% vs. 10.5%, P=0.068, OR: 0.80, 95% CI: 0.60-1.07). On average, the adherent group incurred lower medical costs than the nonadherent group ($3380, 95% CI, $3046-$3750 vs. $4348, 95% CI, $3828-$4940, P=0.003). CONCLUSION:Treatment adherence is associated with better clinical and economic outcomes including lower risks for MS-related hospitalization, MS relapse, and less MS-related medical costs. Treatments that require infrequent administrations and have favorable adherence profiles may benefit patients who are unable to adhere to DMT therapies. Such treatments may be important in improving disease outcomes and may be suitable therapeutic candidates for the management of MS.
journal_name
Adv Therjournal_title
Advances in therapyauthors
Tan H,Cai Q,Agarwal S,Stephenson JJ,Kamat Sdoi
10.1007/s12325-010-0093-7subject
Has Abstractpub_date
2011-01-01 00:00:00pages
51-61issue
1eissn
0741-238Xissn
1865-8652journal_volume
28pub_type
杂志文章,多中心研究abstract:INTRODUCTION:To evaluate the retinal function and the relative neural conduction along the visual pathway after treatment with citicoline in liposomal formulation (CLF) eye drops in patients with open angle glaucoma (OAG). METHODS:Twelve OAG patients (mean age ± standard deviation 52.58 ± 11.39 years, intraocular pres...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-0897-z
更新日期:2019-04-01 00:00:00
abstract:INTRODUCTION:The Medicare Part D prescription plan has a coverage gap from $2250 to $5100 per year (2006 thresholds) in which patients pay full drug costs (the "donut hole"). We examined prescription costs in patients aged >or=65 years with atrial fibrillation (AF), and the proportions entering/exiting the donut hole i...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-009-0054-1
更新日期:2009-08-01 00:00:00
abstract:INTRODUCTION:The purpose of this study was to determine prescribing trends in a specialist glaucoma clinic in the UK. Specifically, the aims were to determine which drugs were prescribed as first-, second-, and third-line treatment, the persistence of first-, second-, and third-line treatment regimens, and the proporti...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-017-0593-9
更新日期:2017-08-01 00:00:00
abstract:INTRODUCTION:Infantile hemangiomas (IH) are the most common benign vascular tumors of childhood, with an incidence of 5-10% during the first year of age. Propranolol is considered the first-line treatment for this condition. Potentially there is a high probability of negative results to therapy, because in many countri...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-016-0391-9
更新日期:2016-10-01 00:00:00
abstract:INTRODUCTION:To assess the risk factors associated with regorafenib-related adverse events (AEs) in metastatic colorectal cancer (mCRC) and gastrointestinal stromal tumors (GIST). We also evaluated different measures of combatting AEs and their success rate to aid physicians in early identification and management of re...
journal_title:Advances in therapy
pub_type: 杂志文章,meta分析
doi:10.1007/s12325-019-01013-5
更新日期:2019-08-01 00:00:00
abstract:INTRODUCTION:Our objective was to determine the effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in a broad range of patient profiles, including subgroups with varying hypertension severity, age and cardiovascular risk profiles. METHODS:Patient data from four large prospective observat...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01527-3
更新日期:2020-11-05 00:00:00
abstract:INTRODUCTION:The aim of this analysis was to characterize the safety and tolerability of empagliflozin in patients with type 2 diabetes mellitus (T2DM) who were randomized to empagliflozin (10/25 mg) or placebo in clinical trials. METHODS:Pooled data from 20 trials were analyzed for patients with T2DM treated with emp...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01329-7
更新日期:2020-08-01 00:00:00
abstract:INTRODUCTION:This retrospective study used data from a primary care database to compare two insulin products in routine clinical practice for the treatment of type 2 diabetes in the UK. PATIENTS AND METHODS:Records were analyzed for patients with type 2 diabetes who had been initiated on biphasic insulin aspart 30 (BI...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-010-0079-5
更新日期:2010-11-01 00:00:00
abstract:INTRODUCTION:Spinal muscular atrophy (SMA) is a neurodegenerative disease of the motor neurons that results in progressive muscle weakness. It is also the leading hereditary cause of infant mortality. Homozygous loss of the survival motor neuron (SMN1) gene causes SMA, and the number of copies of the SMN2 gene modulate...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-008-0030-1
更新日期:2008-03-01 00:00:00
abstract::In this double-blind, randomized, placebo-controlled, prospective study, the clinical efficacy and tolerability of oral Hypericum extract STW 3-VI (Laif) 900 mg once daily was compared with that of placebo. A total of 140 outpatients (94 women; 46 men) with moderate depressive disorders and a 17-item Hamilton Depressi...
journal_title:Advances in therapy
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1007/BF02850158
更新日期:2004-07-01 00:00:00
abstract:INTRODUCTION:ARTOS was an international, prospective, non-interventional, non-controlled observational study designed to determine the effectiveness, safety, and tolerability of moxifloxacin under daily-life conditions in patients with complicated skin and skin structure infections (cSSSIs) treated in Europe, the Middl...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-013-0038-z
更新日期:2013-06-01 00:00:00
abstract::This study was performed to investigate the relationships between markers of inflammation in serum (interleukin-6 [IL-6], interleukin-10 [IL-10], and granulocyte elastase [GE]), severity of injury, and clinical outcomes, and to evaluate the predictive value of these markers for major complications and mortality. This ...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02877699
更新日期:2007-09-01 00:00:00
abstract::Fibroids, the most common tumor in women of reproductive age, impact negatively on women's health and quality of life, and have significant cost implications for their management. The current mainstay treatments are surgical (myomectomy and hysterectomy) and more recently radiological (UAE and focused ultrasound surge...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-012-0042-8
更新日期:2012-08-01 00:00:00
abstract:INTRODUCTION:Partial nephrectomy (PN) has evolved into the surgical standard of care for localized renal lesions. Hemostatic agents (HA) support the surgeon in achieving local hemostasis during PN. We previously reported initial results with the HA Hemopatch® in PN. We now report our experiences with Hemopatch® in a la...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01584-8
更新日期:2020-12-04 00:00:00
abstract:INTRODUCTION:Little has been published on respiratory syncytial virus (RSV) among Medicare patients at high risk (HR) of RSV complications due to age or comorbidity. METHODS:Adult patients (at least 18 years of age) with at least 1 diagnostic code for RSV were identified using the 5% US Medicare database from 2011 thr...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01230-3
更新日期:2020-03-01 00:00:00
abstract::The original article can be found online. ...
journal_title:Advances in therapy
pub_type: 杂志文章,已发布勘误
doi:10.1007/s12325-018-0767-0
更新日期:2018-09-01 00:00:00
abstract:PURPOSE:To evaluate the impact on cost, time, resource use, and clinic workflow of converting the route of drug administration from a neurokinin-1 receptor antagonist (NK-1 RA) 30-min intravenous (IV) infusion to aprepitant IV, and more specifically to IV push, within a multicenter community oncology practice. METHODS...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-020-01377-z
更新日期:2020-07-01 00:00:00
abstract::This interventional study was undertaken to assess the impact of physiotherapy education on the knowledge and attitudes of physiotherapists (PTs) and physiotherapy students (PSs) toward euthanasia. The study, which was conducted during the period between 2004 and 2005, included a total of 494 participants (311 PTs; 18...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/BF02850001
更新日期:2007-01-01 00:00:00
abstract:INTRODUCTION:Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A new formulation of ep...
journal_title:Advances in therapy
pub_type: 杂志文章,多中心研究
doi:10.1007/s12325-013-0029-0
更新日期:2013-05-01 00:00:00
abstract::Multiple, potentially practice-changing cardiology trials have been presented or published over the past year. In this paper, we summarize and place in clinical context, new data regarding management of acute coronary syndrome and ST-elevation myocardial infarction (copeptin assessment, otamixaban, cangrelor, prasugre...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-014-0141-9
更新日期:2014-08-01 00:00:00
abstract:INTRODUCTION:Tumor necrosis factor (TNF-alpha) inhibitors, such as adalimumab, have shown success in treating autoimmune inflammatory diseases but are associated with substantial financial burdens to the healthcare system. Biosimilars, which are highly similar to biologic agents, offer the potential to reduce the finan...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-018-0851-5
更新日期:2019-02-01 00:00:00
abstract:INTRODUCTION:Stimulant medications are the most effective drugs in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and in adults. However, some patients do not respond to this treatment and other patients suffer from adverse effects. Very often there are also comorbid disorders that warrant...
journal_title:Advances in therapy
pub_type: 杂志文章,meta分析,评审
doi:10.1007/s12325-009-0008-7
更新日期:2009-02-01 00:00:00
abstract::Dyspnea is the most common symptom experienced by patients with chronic obstructive pulmonary disease (COPD). To avoid exertional dyspnea, many patients adopt a sedentary lifestyle which predictably leads to extensive skeletal muscle deconditioning, social isolation, and its negative psychological sequalae. This "dysp...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-019-01128-9
更新日期:2020-01-01 00:00:00
abstract:INTRODUCTION:Nivolumab has been approved in patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection, in the adjuvant setting. A pivotal trial compared nivolumab with ipilimumab; however, no head-to-head trial exists comparing nivolumab to observation, a common comp...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-019-01060-y
更新日期:2019-10-01 00:00:00
abstract::The prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in ai...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-009-0074-x
更新日期:2009-10-01 00:00:00
abstract:INTRODUCTION:The primary analysis of a global phase 3 study that evaluated the efficacy and safety of denosumab versus zoledronic acid for preventing skeletal-related events (SREs) in adults with newly diagnosed multiple myeloma (MM) indicated that denosumab was noninferior to zoledronic acid for time to first on-study...
journal_title:Advances in therapy
pub_type: 杂志文章,随机对照试验
doi:10.1007/s12325-020-01395-x
更新日期:2020-07-01 00:00:00
abstract:INTRODUCTION:To compare the 24-h intraocular pressure (IOP) control and tolerability of travoprost/timolol benzalkonium chloride (BAK)-free (TTFC) vs. latanoprost/timolol fixed combination preserved with BAK (LTFC) in open-angle glaucoma patients insufficiently controlled with latanoprost 0.005% monotherapy given once ...
journal_title:Advances in therapy
pub_type: 杂志文章,随机对照试验
doi:10.1007/s12325-014-0125-9
更新日期:2014-06-01 00:00:00
abstract:OBJECTIVES:Because clinical guidelines do not offer clear recommendations for treatment options after discontinuing a tumor necrosis factor (TNF) blocker, this study evaluated treatment patterns within 360 days after discontinuation of TNF-blocker treatment. METHODS:The IMS LifeLink Health Plan Claims database was use...
journal_title:Advances in therapy
pub_type: 杂志文章
doi:10.1007/s12325-014-0110-3
更新日期:2014-04-01 00:00:00
abstract:INTRODUCTION:The traditional model of evaluating treatments based primarily on primary outcome measures has stumbled in its application to rare disease. Rare disease clinical trials face the methodological challenges of small, heterogeneous patient populations and relatively few validated, disease-specific outcome meas...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/s12325-019-00920-x
更新日期:2019-05-01 00:00:00
abstract::Diabetes mellitus is one of the most serious heterogeneous endocrinologic diseases; more than 90% of those given this diagnosis have type 2 diabetes mellitus, usually accompanied by macrovascular and microvascular complications. Because most cases include a 7- to 10-y latency period before disease onset, however, it i...
journal_title:Advances in therapy
pub_type: 杂志文章,评审
doi:10.1007/BF02877709
更新日期:2007-09-01 00:00:00